CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.

BMC Cancer · 2026 · PMC13020245 · PMID 41703509

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Ribociclib + fulvestrant showed a numerically favorable effect but did not reach statistical significance in the network model (SUCRA = 58.87%).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.